Henry O. Gosebruch - Feb 25, 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Signature
Steven L. Scrogham, attorney-in-fact for Henry O. Gosebruch
Stock symbol
ABBV
Transactions as of
Feb 25, 2022
Transactions value $
-$6,733,364
Form type
4
Date filed
3/1/2022, 05:14 PM
Previous filing
Feb 22, 2022
Next filing
May 20, 2022

Transactions Table

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.89 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.94 to $148.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.95 to $149.40 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
F5 Balance in AbbVie Savings program as of January 31, 2022.

Remarks:

The sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).